Astellas Pharma (4503.T), Japan’s No.2 drugmaker, expects cancer drugs to become an additional profit pillar by March 2020 and is open to further acquisitions in Japan and overseas as it looks to strengthen its drug pipeline, its chief executive said on Wednesday.
